Three novel 63 cardiac myosin heavy chain (MHC) gene missense mutations, Phe513Cys, Gly716Arg, and Arg719Trp, which cause familial hypertrophic cardiomyopathy (FHC) are described. One mutation in exon 15 (Phe513Cys) does not alter the charge of the encoded amino acid, and affected family members have a near normal life expectancy. The Gly716Arg mutation (exon 19; charge change of +1) causes FHC in three family members, one of whom underwent transplantation for heart failure. The Arg719Trp mutation (exon 19; charge change of -1) was found in four unrelated FHC families with a high incidence of premature death and an average life expectancy in affected individuals of 38 yr. A comparable high frequency of disease-related deaths in four families with the Arg719Trp mutation suggests that this specific gene defect directly accounts for the observed malignant phenotype. Further, the significantly different life expectancies associated with the Arg719Trp vs. Phe513Cys mutation (P < 0.001) support the hypothesis that mutations which alter the charge of the encoded amino acid affect survival more significantly than those that produce a conservative amino acid change. (J. Clin. Invest. 1994. 93:280-285.)
Introduction
Molecular genetic studies have begun to decipher the broad clinical spectrum of familial hypertrophic cardiomyopathy (FHC) .' Chromosomes 1 (1), 11 (2), 14 (3) , and 15 (4) have been demonstrated to contain disease loci that cause FHC, but specific mutations have only been identified in the A cardiac myosin heavy chain (MHC) gene on chromosome 14. Allelic heterogeneity further contributes to the complexity of the ge- Identification of the full complement of /3 cardiac MHC gene mutations that cause FHC may help in both the elucidation of the pathophysiology of this disorder and the assessment of prognosis. Analyses of genotype and phenotype may in particular provide insights into the molecular basis for cardiac dysfunction in this condition. Studies have detected little correlation between the morphologic characteristics ofthe hypertrophic phenotype seen in four different a cardiac MHC gene mutations (5) , suggesting that the extent and distribution of the cardiac hypertrophy observed in affected individuals reflects the interactions of other genes and/or environmental factors. In contrast, there is recent evidence that genotype can account for the variable patient outcomes observed in different families with FHC. Different missense mutations within the /3 cardiac MHC gene appear to be associated with different life expectancies in affected individuals (6) . Two mutations have been identified (Val606Met [6] and Leu9O8Val; [7] ) that produce a conservative change of the encoded amino acid. The prognosis of individuals with these mutations appears better than that observed in individuals with a /3 cardiac MHC gene mutation that encodes an amino acid with a different charge.
To further elucidate those features of / cardiac MHC gene mutations that impact on the clinical manifestations of FHC, we have studied additional families. Three novel mutations have been identified in six unrelated families. Analyses ofclinical data were informative for two mutations. We report a novel conservative mutation (Phe513Cys) that has little effect on patient survival and a nonconservative mutation (Arg719Trp) that is associated with a significant reduction in life expectancy.
Methods
Clinical evaluation. Consent was obtained in accordance with the local institutional review committees for human subject investigations. Clinical, electrocardiographic and echocardiographic assessments of six families were performed as described previously (3, 8) . The diagnosis of hypertrophic cardiomyopathy was based on the demonstration of unexplained left, right, or biventricular hypertrophy. Blood was obtained from all family members for genetic analyses.
Clinical records and family history were obtained to determine the number of disease-related deaths, and the age at death or current age for all affected individuals in each family. For Kaplan-Meier survival curves, individuals who were resuscitated from cardiac arrest were scored as deceased at the age of their event. Kaplan-Meier product limit survival curves were produced as described (6) .
Detection of mutations. Lymphocytes isolated from peripheral blood samples were used to establish a transformed cell line with Ep-stein-Barr virus as described previously (3) . [ cardiac MHC gene or mRNA sequences were amplified from a proband's transformed lymphocytes by sequential rounds of PCR (9) . Amplified sequences were hybridized to RNA probes transcribed from a normal gene and RNase A protection assays performed as described (6) . Analyses were limited to sequences encoding amino acid residues 1-1,080, which were examined using both sense and antisense riboprobes. Amplified sequences that yielded abnormal RNA cleavage patterns were reanalyzed with new DNA or mRNA isolates to exclude artifacts arising from PCR.
DNA obtained from probands in two families ( 120 and 134) were scanned for mutations in exon 19 and 20 by chemical cleavage as described elsewhere (10, 11 ) . These exons were amplified together and heteroduplexes were formed by a denaturing and reannealing reaction between the PCR template and both sense and antisense radiolabelled probes transcribed from a normal gene. The heteroduplexes were modified separately with hydroxylamine and osmium tetroxide, and the modified products were cleaved with piperidine. Products were resolved by electrophoresis in an 8% polyacrylamide gel.
Mutations identified by RNase protection assays or chemical cleavage were subjected to dideoxy nucleotide sequence analysis. Where possible, the nucleotide change identified by sequencing was independently confirmed by demonstration ofa predicted change in restriction enzyme site or by chemical cleavage ofthe exon containing a mutation. Amino acid sequences were deduced from DNA sequences. Nucleotide and amino acid residues are numbered according to Jaenicke ( 12 Clinical studies of three other FHC families ( 101, 120, and 134) have been previously reported (8, 13, 14) . In addition to the typical signs and symptoms of FHC found in affected members of these families, a high incidence of sudden death and disease-related death has been observed. Of 28 affected individuals in family 101, 19 died prematurely (before age 58); death was sudden in 10 individuals and disease-related in 9 individuals. Of 7 affected individuals from family 120, sudden death occurred in 2 and disease-related death occurred in 1. Death occurred in 12 of 23 affected members of family 134; in 10, death was sudden; in 2, death was disease-related; one survivor in this family was resuscitated from sudden cardiac death at age 15.
Mutation identification. The [B cardiac MHC sequences ofa proband from families AX, AZ, Al, and 101 were screened for missense mutations using RNase protection assays as described previously (6, 9) . Because most ,B cardiac MHC gene mutations have been identified in the amino terminal half of the gene (6), sequences encoding amino acid residues 1-1,080 were analyzed. PCR-amplified sequences that produced unusual RNase protection cleavage products were subcloned and their nucleotide sequences determined. The same abnormal product was observed in RNase protetion assays of probands from families Al and 101, suggesting that they shared the same 1B cardiac MHC gene mutation. Nucleotide sequence analyses confirmed that in the probands from families AI and 120 the cytosine at position 2241 (exon 19) has been mutated to a thymine residue (Fig. 2 A and data not shown) .
The C224 1 T transition abolishes an MspI site found in unaffected individuals (Fig. 3 MHC gene from all members of family AZ demonstrated this SfcI site only in those individuals with FHC. RNase protection assays of the proband from family AX identified a mutation in exon 15 that changes the thymine at position 1624 to a guanine (Fig. 2 C) . Since this transversion does not effect a restriction enzyme site, all family members were studied with RNase protection assays. Only clinically affected individuals were found to have two novel fragments resulting from cleavage ofthe normal 171 -bp product into products of sizes 130 and 41 bp (Fig. 3 C) .
The evidence that these nucleotide changes accounts for FHC is based on three observations. First, each nucleotide change alters an encoded amino acid. The C224 1T mutation in families AlI, 101, 120, and 134 encodes an Arg7 1 9Trp change; the G2232A mutation in family AZ encodes a Gly716Arg change; the T1 624G mutation in family AX encodes a Phe5 1 3Cys change. Two of these missense mutations are nonconservative and alter the charge (Arg7l9Trp, -1 and Gly7 l6Arg, + 1) of the encoded amino acid. Second, each of these missense mutations alters an amino acid that has been conserved in all mammalian myosin molecules studied (data not shown). The PheS 1 3Cys mutation alters a myosin heavy chain residue that has been stringently conserved in all vertebrates. Third, these mutations have not been found in analyses of more than 200 normal chromosomes. Fourth, there is complete concordance between clinical status and genotype in each family.
Survival analyses. To define the natural history of hypertrophic cardiomyopathy due to each of these missense mutations, we compared the survival of affected individuals from each family. Too few individuals with the Gly7 16Arg mutation were present in Family AZ to construct meaningful KaplanMeier survival curves. However we note that one of three affected individuals has required cardiac transplantation for progressive left ventricular wall thinning associated with intractable heart failure. Four unrelated families with FHC resulting from an Arg7l9Tr mutation were identified. Survival of affected individuals in each of these families was similar and (Fig. 5) . A wide range in the distribution and severity of hypertrophy has been observed in affected individuals with the same mutation (3, 5, Table I , and our unpublished data) suggesting a multifactorial etiology to the morphologic features of this disorder. In contrast, analyses of the natural history of FHC in large kindreds and in unrelated families with a common mutation demonstrate that genotype can substantially influence survival. We suggest that ,B cardiac MHC missense mutations can be divided into three groups ( Three benign mutations have been identified, located in the head region (Phe513Cys, exon 15; Val606Met, exon 16 [6] ) or in the head/rod junction (Leu9O8Val, exon 23 [7, 16] ). Each of these is a conservative mutation, suggesting that the lack of charge change may in part account for the good prognosis associated with these mutations. Regional localization may also contribute to a benign phenotype. None ofthe mutations characterized as malignant occur in the head/rod junction and the sole mutation identified in the rod (a 3' deletion [17] ) produces a strikingly late onset ofdisease. Collectively, these data suggest that mutations which arise within the head/rod or rod region are more likely to be benign or may be clinically silent.
Significant premature mortality accompanies three mutations: Arg4O3Gln (exon 13 [15] ), Arg453Cys (exon 14 [6] changes in secondary structure. Alternatively, some mutations may perturb a single myosin function, whereas other mutations may alter several functions and result in a more severe phenotype. Future studies that integrate genetic data, structural modeling, and biochemical studies should more fully elucidate the mechanisms by which mutations perturb myosin physiology and result in significant cardiac pathology. Definition of the full spectrum of (3 cardiac MHC mutations that cause the differing phenotypes found in FHC will contribute to understanding myosin processes. Ultimately this may help to improve therapeutics for the dysfunctional hypertrophic heart. More immediately, a compilation of the clinical outcomes associated with different A cardiac MHC mutations will enable physicians to recognize and treat those individuals at risk for the serious sequelae of FHC.
